NGNazaret Gomez-Martinez

Nazaret Gomez-Martinez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nazaret Gomez-Martinez has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Ana Marti-Pastor

    Internal Medicine Department, Alicante General University Hospital—Alicante Institute of Health and Biomedical Research (ISABIAL), 03010 Alicante, Spain

    1 shared publication
  • Eduardo Climent-Grana

    Pharmacy Department, Alicante General University Hospital—Alicante Institute of Health and Biomedical Research (ISABIAL), 03010 Alicante, Spain

    1 shared publication
  • Esperanza Merino

    Unit of infectious Diseases Dr. Balmis General University Hospital - Alicante Institute of Health and Biomedical Research (ISABIAL), Avda Pintor Baeza, 12, Alicante 03010, Spain; Clinical Medicine Department, Miguel Hernández University, Carretera N-332, s/n , Sant Joan d'Alacant, Alicante 03550, Spain

    1 shared publication
  • Joaquín Portilla

    Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain

    1 shared publication
  • Jos&Eacute Manuel Ramos

    Clinical Medicine Department, Miguel Hernández University of Elche, 03550 Alicante, Spain

    1 shared publication
  • Manuel Priego-Valladares

    Palliative Care Unit and Internal Medicine Department, Alicante General University Hospital—Alicante Institute of Health and Biomedical Research (ISABIAL), 03010 Alicante, Spain

    1 shared publication

Latest Publications

  • Open Access

    Palliative Sedation in COVID-19 End-of-Life Care. Retrospective Cohort Study

    by Jose-Manuel Ramos-Rincon, Oscar Moreno-Perez, Nazaret Gomez-Martinez, Manuel Priego-Valladares, Eduardo Climent-Grana, Ana Marti-Pastor, Joaquin Portilla-Sogorb, Rosario Sanchez-Martinez, Esperanza Merino

    Background and Objectives: Descriptions of end-of-life in COVID-19 are limited to small cross-sectional studies. We aimed to assess end-of-life care in inpatients with COVID-19 at Alicante General University Hospital (ALC) and compare differences according to palliative and non-palliative sedation. Material and Methods: This was a retrospective cohort study in inpatients included in the ALC COVID-19 Registry (PCR-RT or antigen-confirmed cases) who died during conventional admission from 1 March to 15 December 2020. We evaluated differences among deceased cases according to administration of palliative sedation. Results: Of 747 patients evaluated, 101 died (13.5%). Sixty-eight (67.3%) died in acute medical wards, and 30 (44.1%) received palliative sedation. The median age of patients with palliative sedation was 85 years; 44% were women, and 30% of cases were nosocomial. Patients with nosocomial acquisition received more palliative sedation than those infected in the community (81.8% [9/11] vs 36.8% [21/57], p = 0.006), and patients admitted with an altered mental state received it less (20% [6/23] vs. 53.3% [24/45], p = 0.032). The median time from admission to starting palliative sedation was 8.5 days (interquartile range [IQR] 3.0–14.5). The main symptoms leading to palliative sedation were dyspnea at rest (90%), pain (60%), and delirium/agitation (36.7%). The median time from palliative sedation to death was 21.8 h (IQR 10.4–41.1). Morphine was used in all palliative sedation perfusions: the main regimen was morphine + hyoscine butyl bromide + midazolam (43.3%). Conclusions: End-of-life palliative sedation in patients with COVID-19 was initiated quite late. Clinicians should anticipate the need for palliative sedation in these patients and recognize the breathlessness, pain, and agitation/delirium that foreshadow death.